BridgeBio Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.13 Mil. BridgeBio Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,735.71 Mil. BridgeBio Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-1,354.26 Mil.
BridgeBio Pharma's debt to equity for the quarter that ended in Dec. 2023 was -1.28.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BridgeBio Pharma's Debt-to-Equity or its related term are showing as below:
BBIO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.98 Med: -0.56 Max: 8.56
Current: -1.29
During the past 7 years, the highest Debt-to-Equity Ratio of BridgeBio Pharma was 8.56. The lowest was -1.98. And the median was -0.56.
BridgeBio Pharma Debt-to-Equity Historical Data
The historical data trend for BridgeBio Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
BridgeBio Pharma Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
0.23 |
8.56 |
-1.98 |
-1.37 |
-1.29 |
|
BridgeBio Pharma Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-1.37 |
-1.41 |
-1.27 |
-1.44 |
-1.29 |
Competitive Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Debt-to-Equity falls into.
BridgeBio Pharma Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
BridgeBio Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
BridgeBio Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (BridgeBio Pharma) Business Description
Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Executives
| Hannah Valantine |
director |
1305 O'BRIEN DRIVE, MENLO PARK CA 94025 |
| Frank Mccormick |
officer: Chairman of Oncology |
C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001 |
| Randal W Scott |
director |
171 MAIN STREET #225, LOS ALTOS CA 94022 |
| Neil Kumar |
director, officer: See Remarks |
C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
| Brian C Stephenson |
officer: See Remarks |
3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
| Viking Global Opportunities Parent Gp Llc |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Viking Global Investors Lp |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Douglas A. Dachille |
director |
175 WATER STREET, NEW YORK NY 10038 |
| Andrew Lo |
director |
C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
| Ronald J Daniels |
director |
C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901 |
| Fred Hassan |
director |
C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487 |
| James C Momtazee |
director |
2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025 |
| Brent L Saunders |
director |
2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033 |
| Andrea Ellis |
director |
C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301 |
| Richard H Scheller |
director, officer: See Remarks |
C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990 |
BridgeBio Pharma (BridgeBio Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BBIO has been successfully added to your